Table 3C Grade 3 or higher adverse events in at least 3 (6%) patients

From: Mipsagargin, a novel thapsigargin-based PSMA-activated prodrug: results of a first-in-man phase I clinical trial in patients with refractory, advanced or metastatic solid tumours

Adverse event

Number (%) of patients

GGT increased

5 (11.4)

AST increased

4 (9.1)

Anaemia

4 (9.1)

Hyperkalaemia

4 (9.1)

Renal failure acute

3 (6.8)

Thrombocytopenia

3 (6.8)

Abdominal pain

3 (6.8)

Ascites

3 (6.8)

  1. Abbreviations: AST=aspartate aminotransferase; GGT=γ-glutamyl transferase.
  2. Includes both treatment-related and treatment-unrelated adverse events.
Back to article page